ORIL-007O

ORIL-007O is a preclinical oral oncology candidate from Oncology Research International. It is described as an oral formulation of the ORIL-007 program, a saponin-based natural product compound that acts through modification of the cellular plasma membrane and is intended to trigger apoptosis in cancer cells; the specific molecular target has not been publicly disclosed. Public pipeline information identifies ORIL-007O broadly for cancer, without naming specific tumor types, and distinguishes it from other ORIL-007 formulations such as dermal delivery.

Other names

ORIL-007 oral formulationORIL007 oral formulationORIL 007 oral formulation